Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

SYSTEMIC SCLEROSIS

Targeting the TLR4–MD2 axis in systemic sclerosis

Nature Reviews Rheumatology volume 14, pages 564–566 (2018)Cite this article

Subjects

Inappropriate activation of Toll-like receptor 4 (TLR4) on resident fibroblasts, through the binding of damage-associated molecular patterns, is a potential driver of fibrosis in systemic sclerosis. New evidence suggests that targeting fibroblast-specific TLR4 or an accessory molecule MD2 could have therapeutic value.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Targeting TLR4–MD2 signalling in fibroblast activation.

References

  1. Elhai, M. et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 51, 1017–1026 (2012).

    Article  Google Scholar 

  2. O’Reilly, S. Toll like receptors in systemic sclerosis: an emerging target. Immunol. Lett. 195, 2–8 (2018).

    Article  Google Scholar 

  3. Fullard, N. & O’Reilly, S. Role of innate immune system in systemic sclerosis. Sem. Immunopathol. 37, 511–517 (2015).

    Article  CAS  Google Scholar 

  4. Bhattacharyya, S. et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight 3, e98850 (2018).

    Article  Google Scholar 

  5. Bhattacharyya, S. et al. Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am. J. Pathol. 182, 192–205 (2013).

    Article  CAS  Google Scholar 

  6. Bhattacharyya, S. et al. Tenascin-C drives persistence of organ fibrosis. Nat. Commun. 7, 11703 (2016).

    Article  CAS  Google Scholar 

  7. Milano, A. et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3, e2696 (2008).

    Article  Google Scholar 

  8. Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex. Nature 458, 1191 (2009).

    Article  CAS  Google Scholar 

  9. Dowson, C. et al. Innate immunity in systemic sclerosis. Curr. Rheumatol. Rep. 19, 2 (2017).

    Article  Google Scholar 

  10. Opal, S. M. et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA 309, 1154–1162 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northumbria University, Faculty of Health and Life Sciences, Ellison Building, Newcastle Upon Tyne, UK

    Steven O’Reilly

  2. University Medical Centre Utrecht, Department of Rheumatology and Immunology, Utrecht, Netherlands

    Jacob M. van Laar

Authors
  1. Steven O’Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacob M. van Laar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven O’Reilly.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

O’Reilly, S., van Laar, J.M. Targeting the TLR4–MD2 axis in systemic sclerosis. Nat Rev Rheumatol 14, 564–566 (2018). https://doi.org/10.1038/s41584-018-0077-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-018-0077-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing